BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 19372565)

  • 21. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.
    Cui Y; Wu W; Zhou Y; Xie Q; Liu T; Jin J; Liu K
    Future Oncol; 2013 Mar; 9(3):411-8. PubMed ID: 23469976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Biomed Pharmacother; 2016 Oct; 83():22-32. PubMed ID: 27470546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.
    Tillotson B; Slocum K; Coco J; Whitebread N; Thomas B; West KA; MacDougall J; Ge J; Ali JA; Palombella VJ; Normant E; Adams J; Fritz CC
    J Biol Chem; 2010 Dec; 285(51):39835-43. PubMed ID: 20940293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
    Ohba S; Hirose Y; Yoshida K; Yazaki T; Kawase T
    J Neurosurg; 2010 Jan; 112(1):33-42. PubMed ID: 19408974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anticancer effect of 17-(6-cinnamamido-hexylamino-)-17-demethoxygeldanamycin: in vitro and in vivo].
    Li L; Liu H; Zhang SH; Hu L; Zhen YS
    Yao Xue Xue Bao; 2013 Dec; 48(12):1771-7. PubMed ID: 24689233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review).
    He W; Hu H
    Oncol Rep; 2018 Jul; 40(1):3-15. PubMed ID: 29749536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
    Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BIIB021, a novel Hsp90 inhibitor, sensitizes esophageal squamous cell carcinoma to radiation.
    Wang XT; Bao CH; Jia YB; Wang N; Ma W; Liu F; Wang C; Wang JB; Song QX; Cheng YF
    Biochem Biophys Res Commun; 2014 Oct; 452(4):945-50. PubMed ID: 25223594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the impact of HER2 status on the antitumor activity of an HSP90 inhibitor in human tumor xenograft mice using pharmacokinetic-pharmacodynamic modeling.
    Saitoh R; Nagayasu M; Shibahara N; Ono N; Suda A; Kato M; Ishigai M
    Drug Metab Pharmacokinet; 2014; 29(2):185-91. PubMed ID: 24126359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
    Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F
    Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
    Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
    Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
    Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
    Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
    Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
    Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heat Shock Protein 90 Inhibitors AUY922, BIIB021 and SNX5422 Induce Bim-mediated Death of Thyroid Carcinoma Cells.
    Kim SH; Cho YK; Huh JH; Kang JG; Ihm SH; Choi MG; Lee SJ
    Anticancer Res; 2020 Nov; 40(11):6137-6150. PubMed ID: 33109551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
    Scaltriti M; Serra V; Normant E; Guzman M; Rodriguez O; Lim AR; Slocum KL; West KA; Rodriguez V; Prudkin L; Jimenez J; Aura C; Baselga J
    Mol Cancer Ther; 2011 May; 10(5):817-24. PubMed ID: 21383049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
    Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
    Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.